Experimental Alzheimer’s drug from Roche fails in trials

November 14, 2022

(Washington Post) – An experimental Alzheimer’s drug designed to slow cognitive decline failed to meet the goals of two closely watched clinical trials, a discouraging development that underscores the challenges of developing treatments for the memory-robbing disease.